Market capitalization | $907.30m |
Enterprise Value | $1.10b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 5.67 |
EV/Sales (TTM) EV/Sales | 1.58 |
P/S ratio (TTM) P/S ratio | 1.31 |
P/B ratio (TTM) P/B ratio | 1.21 |
Revenue growth (TTM) Revenue growth | 4.40% |
Revenue (TTM) Revenue | $694.96m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
9 Analysts have issued a Pacira Pharmaceuticals, Inc. forecast:
9 Analysts have issued a Pacira Pharmaceuticals, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 695 695 |
4%
4%
|
|
Gross Profit | 459 459 |
12%
12%
|
|
EBITDA | 178 178 |
15%
15%
|
EBIT (Operating Income) EBIT | 102 102 |
51%
51%
|
Net Profit | -91 -91 |
1,400%
1,400%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Pacira Biosciences, Inc. develops and manufactures injectable therapeutic products. The firm engages in the development, commercialization and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ.
Head office | United States |
CEO | Frank Lee |
Employees | 712 |
Founded | 2006 |
Website | www.pacira.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.